Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against covid19 and other respiratory infections

HIGHLIGHTS

• who: David Needham from the To measure the extraction of niclosamide from Yomesan tablets in Trisu2011buffered solution at nominal pH , over a range of niclosamideu2011equivalent concentrations (, u00b5M, u00b5M, and , mM) Experiments were designed to demonstrate that niclosamide can be obtained in supernatant solution at potentially efficacious oral and nasal spray concentrations, i.e., ~ , u00b5M at pH, ., for nasal, and up to , u00b5M at pH, ., for oral administration. Excess amounts of Yomesan powder were added to the buffers at niclosamide-equivalent concentrations of , u00b5M, u00b5M, and , mM. These concentrations were based on the pH-dependent total solubility limits . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.